ThermoGenesis Holdings, Inc. (THMO)
Stock Price Chart
Key Info
| Market Cap | 39.21M |
| Revenue (ttm) | 13.29M |
| Net Income (ttm) | -12.23M |
| Shares Out | 6.37M |
| EPS (ttm) | n/a |
| PE Ratio | n/a |
| Forward PE | 31.75 |
| Dividend | n/a |
| Dividend Yield | n/a |
Stock Quote
| Trading Day | Aug 7, 2020 |
| Last Price | $6.16 |
| Previous Close | $5.65 |
| Change ($) | 0.51 |
| Change (%) | 9.03% |
| Day's Open | 5.68 |
| Day's Range | 5.65 - 6.30 |
| Day's Volume | 706,435 |
| 52-Week Range | 1.63 - 14.18 |
More Stats
| Market Cap | 39.21M |
| Enterprise Value | 37.97M |
| Earnings Date (est) | Aug 12, 2020 |
| Ex-Dividend Date | n/a |
| Shares Outstanding | 6.37M |
| Float | 4.00M |
| EPS (basic) | n/a |
| EPS (diluted) | n/a |
| FCF / Share | -0.85 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
| Payout Ratio | n/a |
| Shares Short | 187,614 |
| Short Ratio | 0.42 |
| Short % of Float | 3.45% |
| Beta | 3.33 |
| PE Ratio | n/a |
| Forward PE | 31.75 |
| P/FCF Ratio | n/a |
| PS Ratio | 2.95 |
| PB Ratio | 8.15 |
| Revenue | 13.29M |
| Operating Income | -5.03M |
| Net Income | -12.23M |
| Free Cash Flow | -3.53M |
| Net Cash | 1.23M |
| Net Cash / Share | 0.19 |
| Gross Margin | 42.88% |
| Operating Margin | -37.84% |
| Profit Margin | -92.00% |
| FCF Margin | -26.53% |
| ROA | -13.35% |
| ROE | -235.12% |
| ROIC | -59.40% |
Analyst Summary
Analyst Consensus: Buy
Financial Performance
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 13.05 | 9.67 | 14.53 | 11.93 | 16.04 | 15.99 | 17.96 | 19.02 | 23.40 | 23.09 |
| Revenue Growth | 34.89% | -33.41% | 21.76% | -25.64% | 0.34% | -11% | -5.57% | -18.71% | 1.35% | - |
| Gross Profit | 5.70 | 2.19 | 5.84 | 2.74 | 4.75 | 5.89 | 6.37 | 6.33 | 8.84 | 7.45 |
| Operating Income | -4.73 | -43.55 | -9.37 | -10.87 | -14.86 | -9.04 | -5.23 | -5.38 | -2.84 | -5.25 |
| Net Income | -9.50 | -39.72 | -29.10 | -18.59 | -14.85 | -8.63 | -3.09 | -4.99 | -2.57 | -5.19 |
| Shares Outstanding | 2.83 | 1.84 | 0.89 | 0.25 | 0.20 | 0.12 | 0.08 | 0.08 | 0.07 | 0.07 |
| Earnings Per Share | -3.36 | -21.57 | -32.70 | -75.70 | -73.60 | -72.00 | -38.00 | -60.00 | -34.00 | -74.00 |
| Operating Cash Flow | -3.26 | -6.98 | -7.22 | -9.63 | -10.65 | -7.84 | -3.08 | -3.89 | -2.09 | -4.43 |
| Capital Expenditures | -0.18 | -1.24 | -0.38 | -0.71 | -0.59 | -0.40 | -0.39 | -0.55 | -0.25 | -0.47 |
| Free Cash Flow | -3.44 | -8.22 | -7.59 | -10.34 | -11.24 | -8.24 | -3.47 | -4.43 | -2.34 | -4.90 |
| Cash & Equivalents | 4.16 | 2.40 | 3.62 | 5.84 | 3.36 | 14.81 | 6.88 | 7.88 | 12.31 | 10.73 |
| Total Debt | 5.69 | 1.17 | 3.50 | 2.49 | - | - | - | - | - | - |
| Net Cash / Debt | -1.54 | 1.23 | 0.12 | 3.35 | 3.36 | 14.81 | 6.88 | 7.88 | 12.31 | 10.73 |
| Assets | 15.21 | 14.61 | 46.93 | 49.90 | 50.76 | 62.89 | 18.53 | 21.08 | 24.40 | 24.03 |
| Liabilities | 14.30 | 7.88 | 16.10 | 17.63 | 15.86 | 14.19 | 5.21 | 5.18 | 4.31 | 6.25 |
| Book Value | 0.39 | 8.44 | 30.84 | 32.27 | 34.90 | 48.70 | 13.32 | 15.90 | 20.09 | 17.78 |
Company Profile
Company Details
| Full Name | ThermoGenesis Holdings, Inc. |
| Country | United States |
| Employees | 50 |
| CEO | Xiao Chun Xu |
Stock Information
| Ticker Symbol | THMO |
| Stock Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Medical Devices |
| Unique Identifier | NASDAQ: THMO |
Description
ThermoGenesis Holdings, Inc. develops, commercializes, and markets a range of automated technologies for chimeric antigen receptor (CAR)-T and other cell-based therapies. It markets a suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology, including its semi-automated, functionally closed CAR-TXpress platform, which streamlines the manufacturing process for the emerging CAR-T immunotherapy market. The company operates through two segments, Device and Clinical Development. It manufactures and markets products for clinical bio-banking applications, including AXP Automated Cell Separation System, an automated cell separation system for isolating and retrieving stem and progenitor cells from umbilical cord blood; and BioArchive Automated Cryopreservation System, an automated, robotic, liquid nitrogen controlled-rate-freezing, and cryogenic storage system for cord blood samples and cell therapeutic products used in clinical applications. The company also offers PXP Point-of-Care System, an automated sterile system that allows for the automated processing of autologous peripheral blood or bone marrow aspirate derived stem cells at the point-of-care, such as surgical centers or clinics; and X-Series products, such as X-Lab for cell isolation, X-Wash System for cell washing and reformulation, X-Mini for small scale cell purification, and X-BACS System under development for large scale cell purification using the company's proprietary buoyance-activated cell sorting (BACS) technology. In addition, it provides AR-TXpress Platform that addresses the critical unmet need for large scale cellular processing and chemistry, manufacturing, and controls needs. The company was formerly known as Cesca Therapeutics Inc. and changed its name to ThermoGenesis Holdings, Inc. in November 2019. ThermoGenesis Holdings, Inc. was founded in 1986 and is headquartered in Rancho Cordova, California.